Another important aspect of the use of RLR ligands in cancer therapy is that apoptosis induced by RLRs receptors is independent of the mutational status of the p53 gene, mutations of which are responsible for the resistance of cancer cells to chemotherapy and radiotherapy-induced apoptosis. This evidence concerns the gene DHX58 and cancer.